141 related articles for article (PubMed ID: 35818348)
1. Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device.
Jokimäki A; Iivanainen S; Mikkonen R; Mika K; Koivunen J
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1677. PubMed ID: 35818348
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device.
Matsuoka A; Mitsuma A; Maeda O; Kajiyama H; Kiyoi H; Kodera Y; Nagino M; Goto H; Ando Y
Cancer Sci; 2016 Oct; 107(10):1453-1457. PubMed ID: 27412083
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
6. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
9. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
11. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control.
Müller J; Kreutz C; Ringhof S; Koeppel M; Kleindienst N; Sam G; Schneeweiss A; Wiskemann J; Weiler M
Sci Rep; 2021 Jan; 11(1):2398. PubMed ID: 33504885
[TBL] [Abstract][Full Text] [Related]
13. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data.
Wang M; Bandla A; Sundar R; Molassiotis A
Eur J Oncol Nurs; 2022 Oct; 60():102196. PubMed ID: 36067640
[TBL] [Abstract][Full Text] [Related]
14. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
[TBL] [Abstract][Full Text] [Related]
15. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
16. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
[TBL] [Abstract][Full Text] [Related]
17. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.
Gewandter JS; Chaudari J; Ibegbu C; Kitt R; Serventi J; Burke J; Culakova E; Kolb N; Sluka KA; Tejani MA; Mohile NA
Support Care Cancer; 2019 May; 27(5):1765-1774. PubMed ID: 30151681
[TBL] [Abstract][Full Text] [Related]
18. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]